BOLD compared with LYEL: revenue, margins and what each company keeps, and the suppliers and customers both name

BOLDBoundless Bio, Inc.

Mkt capRevenueRevenue

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

Compare

BOLDBoundless Bio, Inc.

LYELLyell Immunopharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BOLD

No earnings history for BOLD.

LYEL2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±28.5%▼−2.79%×0.10

Q2 FY26±35.4%▲+3.52%×0.10

= impliedBOLD realized, solidLYEL realized, hatchedOne scale, both sides: full bar = 36%× = |realized| ÷ impliedSource: market data

BOLDBoundless Bio, Inc.

2.44▲+1.27%· post 2.44

Mkt cap$56.0MRevenue—Revenue—

LYELLyell Immunopharma, Inc.

14.85▼−1.03%· post 14.85

ClosedNov 6 '26

Mkt cap$365.3MRevenue$3,000Q3 FY26Revenue$36,000FY25

Compare

ClosedNov 6 '26

BOLDBoundless Bio, Inc.

LYELLyell Immunopharma, Inc.

2.44▲+1.27%post 2.44

Price

14.85▼−1.03%post 14.85

$56.0M

Mkt cap

$365.3M

—

Revenue

$3,000Q3 FY26

—

Revenue

$36,000FY25

BOLD2.44▲+1.27%vsLYEL14.85▼−1.03%ClosedNov 6 '26